Also mentioned that "the ACE2 affinity for these strains are similar to the affinity of their parental strains." Hoping that means that they will target upper rather than lower respiratory tract. At least, I think that is what it means. This time around, anyway.Journal pre-proof manuscript in the journal Cell just dropped: "Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants"
In summary:
The researchers first evaluated the neutralisation of these four new subvariants by sera from five different clinical cohorts.
Quoting DG Alerts summary of the research (https://dgalerts.docguide.com/ncov-...covid-19-vaccines-including-bivalent-vaccines):
- individuals who received three doses of the original coronavirus disease 2019 (COVID-19) mRNA vaccines (3 shots WT; n = 14)
- individuals who received four doses of the original COVID-19 mRNA vaccines (4 shots WT; n = 19)
- individuals who received one of the recently authorised bivalent (WT and BA.5) COVID-19 mRNA vaccines as a 4th shot after three doses of the original COVID-19 mRNA vaccines (3 shots WT + bivalent; n = 21),
- patients who had BA.2 breakthrough infection after receiving two to three doses of the original COVID-19 mRNA vaccines (BA.2 breakthrough; n = 14)
- patients who had BA.4 or BA.5 breakthrough infection after receiving three to four doses of the original COVID-19 mRNA vaccines (BA.4/5 breakthrough; n = 20).
"The study demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BQ.1, BQ.1.1, XBB, and XBB.1 subvariants were “barely susceptible” to neutralisation by sera from vaccinated individuals with or without prior infection, including those recently boosted with the new bivalent (WA1-BA.5) mRNA vaccines.
In addition, the study led by Qian Wang, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, showed that these new subvariants were completely or partially resistant to neutralisation by most monoclonal antibodies tested, including those with Emergency Use Authorization."
Happy Holidays!
In addition: the authors pointed out that “although infections may now be more likely, COVID-19 vaccines have been shown to remain effective at preventing hospitalization and severe disease even against Omicron as well as possibly reducing the risk of post-acute sequelae of COVID-19 (long COVID)."